Bendamustine effective for some B-cell patients



Results from a study published in the journal Cancer suggest that patients with indolent B-cell non-Hodgkin’s lymphoma (iNHL) are responding well to Bendamustine, a chemo drug generally used to treat chronic lymphocytocic leukemia and some NHLs.


Professor Brad S. Kahl of the University of Wisconsin School of Medicine and Public Health, Maddison, USA


100 patients aged 31-84 years with indolent NHL who had undergone an average of two chemotherapies prior to enrolment and all were rituximab-refractory.


Drug: Bendamustine, a nitrogen mustard anticancer alkylating agent.
Regimen: The patients received intravenous infusions over 60-120 minutes, of bendamustine 120mg/m2 on days one and two every 21 days, for six to eight cycles.


Overall response rate (ORR): 75%
Complete response: 14%
Unconfirmed complete response: 3%
Partial response: 58%


Grade III or IV reversible haematological toxicities included:
-- Neutropenia (61%)
-- Thrombocytopenia (25%)
-- Anaemia (10%).

The most frequent non-haematological adverse events (any grade) included:
-- Nausea (77%)
-- Infection (69%)
-- Fatigue (64%)
-- Diarrhoea (42%)
-- Vomiting (40%)
-- Pyrexia (36%)
-- Constipation (31%)
-- Anorexia (24%).


Two of every three patients who had become rituximab-refractory responded well to the Bendamustine, and that's a good sign since rituximab immunotherapy is cutting edge stuff.

In one sense it's good to see there's another treatment option for B-cell patients whose lymphomas have become daity-refractory, but by and large this looks like little more than the pharmaceutical company's efforts to get their drugs approved for as many maladies as possible, since this iinevitably means more profits.

by Ross Bonander

More Articles

More Articles

According to a study by Japanese researchers, the SMILE combination chemotherapy protocol is effective against extranodal natural killer/T-cell...

Patients treated with maintenance rituximab had three times longer progression-free survival. This is a summary of an article published in the...

When you consider that the adult human body has anywhere from 300 to 700 lymph nodes, the better question might not be where ARE they located, but...

This entry looks at a non-Hodgkin's lymphoma called true histiocytic lymphoma (THL), also referred to as diffuse histiocytic lymphoma, and...

Lymphomatous meningitis [LM], also known as leukemic meningitis, is an extremely serious peripheral cancer that attacks the tissue that covers the...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Intravascular lymphoma is a subtype of 'Lymphoma', an umbrella term that loosely refers to several dozen...

While the average lifespan for hamsters is only about 2.5 years, and they are therefore less prone to long-term illnesses, it is possible for a...

Burkitt's lymphoma is an aggressive B-cell lymphoma that is common in children...

Lymphoma is a cancer of the lymphatic system, causing B-cell or...

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Lymphoma is a life-threatening disease, but is very treatable in most cases. The 5-year survival for patients diagnosed with non-Hodgkin's...

T cell lymphoma treatment options for these cancers are not especially effective and there is no absolute consensus about optimal treatments for...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Lymphomas can arise from most any lymphatic tissue (lymph nodes, spleen, thymus, mucosa associated lymphoid...